

Key highlights of data accepted by ESMO include:

Medicine	Abstract title	Abstract Number/ Presentation Details
Pluvicto™ (lutetium (¹⁷⁷ Lu) vipivotide tetraxetan)	Phase 3 trial of [¹⁷⁷ Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAAddition)	#LBA6 Presidential Symposium 2 (Proffered Paper session) October 19, 2025 16:30 – 18:15 CEST
Pluvicto™ (lutetium (¹⁷⁷ Lu) vipivotide tetraxetan)	Associations between quantitative baseline ⁶⁸ Ga-PSMA-11 PET parameters and ¹⁷⁷ Lu-PSMA-617 efficacy in the PSMAfore Study	#2390P Poster Presentation October 18, 2025 09:00 – 17:00 CEST
Pluvicto™ (lutetium (¹⁷⁷ Lu) vipivotide tetraxetan)	Final analysis of patients treated with [¹⁷⁷ Lu]Lu-PSMA-617 in early access program in metastatic castration-resistant prostate cancer (mCRPC) in France	#2389P Poster Presentation October 18, 2025 09:00 – 17:00 CEST
[²²⁵ Ac]-PSMA-617	PSMAcTION trial-in-progress: a phase 2/3 randomized trial of [²²⁵ Ac]Ac-PSMA-617 (²²⁵ Ac-PSMA-617) versus standard of care in patients with PSMA-positive metastatic castration-resistant prostate cancer who progressed on or after [¹⁷⁷ Lu]Lu-PSMA therapy	#2516TiP Poster Presentation October 18, 2025 09:00 – 17:00 CEST
Kisqali® (ribociclib)	Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2– early breast cancer (EBC): NATALEE 5-year outcomes	#LBA14 Proffered Paper session October 17, 2025 14:00 – 15:30 CEST
Kisqali® (ribociclib)	Impact of neoadjuvant chemotherapy (NACT) response on clinical outcomes with ribociclib (RIB) in HR+/HER2– EBC: a subgroup analysis from the phase 3 NATALEE trial	#366P Poster Presentation October 20, 2025 09:00 – 17:00 CEST
Kisqali® (ribociclib)	A NATALEE data-based machine learning (ML) model to predict distant recurrence (DR) and treatment (tx) effect in real-world (RW) patients (pts) with HR+/HER2– early breast cancer (EBC) without CDK4/6 inhibitor (CDK4/6i) tx	#372P Poster Presentation October 20, 2025 09:00 – 17:00 CEST
Kisqali® (ribociclib)	Real-world characteristics, treatments and outcomes of NATALEE and monarchE-eligible HR+/HER2- early breast cancer patients in the hospital district of Helsinki and Uusimaa (HUS), Finland	#360P Poster Presentation October 20, 2025 09:00 – 17:00 CEST
Kisqali® (ribociclib)	Risk of Recurrence (ROR) After Neoadjuvant Ribociclib Plus ET in Clinically High-Risk ER+/HER2– BC: Preliminary Analysis of the SOLTI-RIBOLARIS Trial	#296O Proffered Paper session October 17, 2025 14:00 – 15:30 CEST